Similarly, mutations in the BCR-ABL kinase domain and submicroscopic chromosomal segmental imbalances have been documented to negatively impact on treatment outcomes in CML patients (Kolomietz et al., 2001; Soverini et al., 2009; Nadarajan et al., 2011). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.